|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
165
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
484
|
April 30, 2026
|
|
Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice -Pub
|
|
5
|
448
|
April 30, 2026
|
|
N-Nitroso dially amine estimation by LCMS
|
|
2
|
90
|
April 29, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
128
|
April 29, 2026
|
|
Something in the air−Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessment-Pub
|
|
2
|
405
|
April 28, 2026
|
|
Nitrosamine limit in the specification based on intermediate and accelerated stability condition results
|
|
4
|
225
|
April 28, 2026
|
|
How to overcome blank interference at NDBA
|
|
4
|
187
|
April 27, 2026
|
|
🇯🇵 Current Nitrosamine Landscape in Japan?
|
|
186
|
17426
|
April 26, 2026
|
|
Removal of nitrosamine analysis from the specification
|
|
3
|
233
|
April 24, 2026
|
|
Regulatory Flexibilities and Clarifications: Chemistry, Manufacturing and Control (CMC) Information for Original First in Human (FIH) Phase 1 INDs
|
|
0
|
200
|
April 23, 2026
|
|
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form -Pub
|
|
4
|
1005
|
April 21, 2026
|
|
Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern -Pub
|
|
0
|
161
|
April 21, 2026
|
|
Kinetic reaction rates for nitrosamine formation using secondary amines pKa
|
|
3
|
350
|
April 21, 2026
|
|
About the amlodipine nitrosamines
|
|
3
|
229
|
April 21, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
462
|
April 20, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
8
|
601
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
202
|
April 20, 2026
|
|
Etelcalcetide Nitroamide – is this possible?
|
|
0
|
77
|
April 18, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
206
|
April 17, 2026
|
|
🇺🇸 FDA Workshop - Nitrosamine-driven Reformulation and Bioequivelance
|
|
1
|
246
|
April 17, 2026
|
|
Toxycologist ... not for you!
|
|
2
|
241
|
April 17, 2026
|
|
Regarding the structural determination of N-nitrosyl abecacil
|
|
0
|
71
|
April 15, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
120
|
April 14, 2026
|
|
Testing of APIs for NDSRI
|
|
5
|
1334
|
April 12, 2026
|
|
FDA CRCG Workshop on Bioequivalence Innovations for Generic Oral Products
|
|
0
|
113
|
April 11, 2026
|
|
AMES Test Study Designs for Nitrosamine Mutagenicity Testing -Pub
|
|
13
|
1635
|
April 9, 2026
|
|
Excipient Selection Strategies to Mitigate Nitrosamine Risks
|
|
0
|
210
|
April 8, 2026
|
|
Would EDTA disodium form nitrosamines?
|
|
13
|
4535
|
April 8, 2026
|
|
N-Nitroso meglumine
|
|
26
|
2380
|
April 8, 2026
|